{
    "nctId": "NCT02072811",
    "officialTitle": "Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells",
    "inclusionCriteria": "* Adult acute myeloid leukemia\n* Age: \u226518 and \u2264 60\n* Clinical condition of the patient allows to carry out induction therapy: ECOG performance status: \u2264 2 and the Hematopoietic Cell Transplant-Co-morbidity Index (HCT-I): \u22643\n* Informed consent to participate in the study (ICF signed)\n* The second early induction start criteria is in addition to the listed above, the percentage of the blasts on the level \\>10% on 7th day.\n* Must have minimum age of 18 Years\n* Must have maximum age of 60 Years",
    "exclusionCriteria": "* No informed consent for participation in the study, mental illness, which don't allow to obtain informed consent and conduct the treatment according to the protocol\n* Pregnancy\n* HIV infection\n* Active cancer\n* Active hepatitis virus infection"
}